호르몬 피임약 시장 예측(-2030년) : 제품 유형, 호르몬, 연령대, 성별, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Hormonal Contraceptives Market is accounted for $18.3 billion in 2023 and is expected to reach $28.2 billion by 2030 growing at a CAGR of 6.3% during the forecast period. Birth control treatments that work on the endocrine system are called hormonal contraceptives. These techniques involve using hormones that women typically make, including progesterone and estrogen to stop ovulation and pregnancy. Hormonal contraception alters the uterus, decreasing the possibility of pregnancy. Hormonal contraceptives come in several forms, including skin-attached patches, pills, injections, arm implants, and intrauterine devices. These hormonal contraceptive methods are trustworthy and safe for preventing pregnancy. Over 99% of unwanted pregnancies are avoided when hormonal contraceptives are used.

According to the World Health Organization, modern contraception rose from 54% in 1990 to 57.4% in 2015 globally.

Market Dynamics:

Driver:

Rising global population

The world's population continues to grow, and this demographic trend has contributed to the increasing demand for effective birth control methods. Hormonal contraceptives have gained popularity due to their reversible nature, ease, and effectiveness in helping people control the size of their families and postpone or space out pregnancies. As individuals strive to achieve their desired family size and improve their socioeconomic conditions, access to effective contraception becomes crucial. These factors propel market demand.

Restraint:

Associated side effects

Potential drawbacks include thrush, or vaginal yeast infections, along with side effects like headaches, nausea, and sore breasts. In addition to causing mood swings and spotting in between periods, the hormones may lessen women's desire for sex. Additionally, there is a slight chance that blood clots (thrombosis) will form. Women who smoke, are extremely overweight, or have a family history of vascular disease are more likely to be at risk than women over 40. Therefore, these related drawbacks might hinder market expansion.

Opportunity:

Technological innovations

New and enhanced hormonal contraceptive methods have been made available as a result of advancements in pharmaceutical research and development. Low-dose formulations, long-acting reversible contraceptives (LARCs), including hormonal IUDs and contraceptive implants, and cutting-edge delivery methods like Trans dermal patches are some of them. Technological innovations have increased consumer choice and promoted market expansion.

Threat:

Regulatory policies and restrictions

The market may be severely impacted by laws and regulations limiting the supply and use of hormonal contraceptives. Hormonal contraception use is restricted or hindered in many countries due to strict rules or cultural and religious beliefs. However, these limitations may impede the expansion of the market and restrict the availability of hormonal contraceptives to those who require them.

COVID-19 Impact

Due to the drop in family planning and the necessity to avoid unwanted pregnancies during the pandemic, COVID-19 has had a little negative overall influence on the market for hormonal contraceptives. These contraceptives are mostly used in family planning. Clinic closures, appointment cancellations, and a shortage of healthcare practitioners may have restricted access to contraception, particularly hormonal contraceptives. This restriction on access might have led to a decline in the market for hormonal contraceptives or an increase in the use of less potent forms of birth control.

The oral contraceptive pills segment is expected to be the largest during the forecast period

The oral contraceptive pills segment is estimated to hold the largest share. OCPs have been available for a number of decades and are among the most popular types of hormonal contraceptives. Oral contraceptive pills are a popular option for people looking for dependable contraception because they are quite effective when used appropriately and consistently. They function by inhibiting ovulation, thickening cervical mucus, and weakening the uterine lining, all of which block sperm from getting to the egg. Oral contraceptive pills are taken daily; most formulations require 21 days of active pills, followed by a week of hormone-free or placebo pills.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to have lucrative growth during the forecast period. The main factors contributing to segmental growth are the expanding unmet need for these hormonal forms of contraception, women's preference for irreversible contraception in emerging economies, the introduction of innovative intrauterine devices by corporations like Allergen and Bayer AG, and the development of multispecialty hospitals. Furthermore, due to the increasing investment in hospital pharmacy improvement, particularly in developing nations.

Region with largest share:

North America commanded the largest market share during the extrapolated period due to factors like the high rate of hormonal contraception uptake, the strong presence of industry players in the area, and superior healthcare infrastructure. Hormonal contraceptives have a well-established organization in North America. The region benefits from a high level of acceptance and knowledge of contraceptive methods and reasonably simple access to hormonal contraceptives via pharmacies and healthcare practitioners. A variety of contraceptive methods, such as oral tablets, patches, injections, and intrauterine devices (IUDs), are available in the North American market.

Region with highest CAGR:

Europe is expected to witness profitable growth over the projection period. Hormonal contraception sales are thriving and varied across Europe. Different European nations have different cultural and legal conventions around contraception, which causes variations in the availability of the product, prescription requirements, and patterns of use. Major pharmaceutical businesses that produce and market hormonal contraceptives are also heavily represented in the region. A variety of contraceptive techniques, such as oral tablets, patches, rings, and implants, are usually available in European countries.

Key players in the market

Some of the key players in the Hormonal Contraceptives Market include: Bayer Healthcare Pharmaceuticals, Amgen, Cipla Limited, Novartis AG, Glenmark Pharmaceuticals, Pfizer, Inc., Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Piramal Healthcare Limited, Teva Pharmaceutical Industries, Abbvie Inc., Organon group of companies, Agile Therapeutics, Janssen Pharmaceutical, Inc., Pregna International Limited, Pantarhei Bioscience and Mayne Pharma Group Limited.

Key Developments:

In May 2021, Pantarhei Bioscience made an announcement that the company got the approval for new oral contraceptive Estelle from the European Commission. With the approval of Estelle, contraceptive can be marketed in all the European states.

In April 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals announced the approval by U.S Food and Drug Administration (FDA) for oral contraceptive NEXTSTELLIS. It is the only contraceptive pill containing estetrol, which is produced from a plant source.

Product Types Covered:

• Injectable Birth Control
• Oral Contraceptive Pills
• Vaginal Rings
• Emergency Contraceptive Pills
• Transdermal Patches
• Combined Oral Contraceptives
• Implanted Contraceptives
• Intrauterine

Hormones Covered:

• Estrogens
• Androgens
• Gonadotropins
• Progestogens
• Antiandrogens
• Other Hormones

Age Groups Covered:

• 15 To 24 Years
• 25 To 34 Years
• 35 To 44 Years
• Above 44 Years

Genders Covered:

• Female
• Male

End Users Covered:

• Household
• Hospitals
• Clinics
• Retail Pharmacies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Hormonal Contraceptives Market, By Product Type

• 5.1 Introduction
• 5.2 Injectable Birth Control
• 5.3 Oral Contraceptive Pills
• 5.4 Vaginal Rings
• 5.5 Emergency Contraceptive Pills
• 5.6 Transdermal Patches
• 5.7 Combined Oral Contraceptives
• 5.8 Implanted Contraceptives
• 5.9 Intrauterine

6 Global Hormonal Contraceptives Market, By Hormone

• 6.1 Introduction
• 6.2 Estrogens
• 6.3 Androgens
• 6.4 Gonadotropins
• 6.5 Progestogens
• 6.6 Antiandrogens
• 6.7 Other Hormones

7 Global Hormonal Contraceptives Market, By Age Group

• 7.1 Introduction
• 7.2 15 To 24 Years
• 7.3 25 To 34 Years
• 7.4 35 To 44 Years
• 7.5 Above 44 Years

8 Global Hormonal Contraceptives Market, By Gender

• 8.1 Introduction
• 8.2 Female
• 8.3 Male

9 Global Hormonal Contraceptives Market, By End User

• 9.1 Introduction
• 9.2 Household
• 9.3 Hospitals
• 9.4 Clinics
• 9.5 Retail Pharmacies
• 9.6 Other End Users

10 Global Hormonal Contraceptives Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Bayer Healthcare Pharmaceuticals
• 12.2 Amgen
• 12.3 Cipla Limited
• 12.4 Novartis AG
• 12.5 Glenmark Pharmaceuticals
• 12.6 Pfizer, Inc.
• 12.7 Lupin Pharmaceuticals, Inc.
• 12.8 Sun Pharmaceutical Industries Ltd.
• 12.9 Piramal Healthcare Limited
• 12.10 Teva Pharmaceutical Industries
• 12.11 Abbvie Inc.
• 12.12 Organon group of companies.
• 12.13 Agile Therapeutics
• 12.14 Janssen Pharmaceutical, Inc.
• 12.15 Pregna International Limited
• 12.16 Pantarhei Bioscience
• 12.17 Mayne Pharma Group Limited